D A Berry
Affiliation: Baylor College of Medicine
- Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342Eric P Winer
Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
J Clin Oncol 22:2061-8. 2004..Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer...
- HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 18:3471-9. 2000..Tamoxifen assignment was not randomized-physician discretion was used for premenopausal and postmenopausal women. Trial protocol then specified assignment to postmenopausal women with ER-positive tumors, although not all took tamoxifen...
- High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant RegistryDonald A Berry
University of Texas M D Anderson Cancer Center, Houston, 77030, USA
J Clin Oncol 20:743-50. 2002..To assess survival of patients with metastatic breast cancer treated with high-dose chemotherapy (HDC) versus standard-dose chemotherapy (SDC)...
- Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancerT Hamaoka
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Br J Cancer 102:651-7. 2010....
- Role of detection method in predicting breast cancer survival: analysis of randomized screening trialsYu Shen
Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Natl Cancer Inst 97:1195-203. 2005..Method of detection appears to be an important prognostic factor, even after adjusting for known tumor characteristics. This finding suggests that clinical trialists should routinely collect information about method of detection...
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry
University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
JAMA 295:1658-67. 2006..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
- Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experienceWenli Dong
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Epidemiol Biomarkers Prev 17:1096-103. 2008..To assess the effect of tumor detection method (screening versus symptom-based diagnosis) in predicting breast cancer survival and investigate how biological features of breast cancer are related to the tumor detection method...
- Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier
Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
J Clin Oncol 23:8331-9. 2005..72 in the validation set and outperformed other prediction tools (P = .02). CONCLUSION: Our nomograms predict pCR accurately and can serve as a basis to integrate future molecular markers into a clinical prediction model...
- Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group BRaymond B Weiss
Walter Reed Army Medical Center, Washington, DC, USA
J Clin Oncol 21:1825-35. 2003....
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and LeukemiaMarc L Citron
ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
J Clin Oncol 21:1431-9. 2003....
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerI Craig Henderson
University of California at San Francisco, San, Francisco, CA 94143, USA
J Clin Oncol 21:976-83. 2003..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
- Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B ExperienceHyman B Muss
University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
J Clin Oncol 25:3699-704. 2007..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
- HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
N Engl J Med 357:1496-506. 2007..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
- Limited family structure and breast cancer riskEdwin S Iversen
JAMA 298:2007; author reply 2007-8. 2007
- Validity of models for predicting BRCA1 and BRCA2 mutationsGiovanni Parmigiani
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
Ann Intern Med 147:441-50. 2007..At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood...
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by Minetta C Liu
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
Cancer Treat Rev 34:223-30. 2008..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
- BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genesDonald A Berry
Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 20:2701-12. 2002....
- Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group BMichael P Digiovanna
Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
J Clin Oncol 26:2364-72. 2008....
- Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group BBlase N Polite
The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
J Clin Oncol 26:2659-65. 2008..This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials...
- Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancerThomas B Julian
Allegheny Breast Care Center, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, USA
J Clin Oncol 26:3338-45. 2008..We present the results from a large, prospective evaluation of the first rapid molecular SLN test, the Breast Lymph Node (BLN) Assay...
- A parallel phase I/II clinical trial design for combination therapiesXuelin Huang
Department of Biostatistics and Applied Mathematics, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Biometrics 63:429-36. 2007..The simulations show that the proposed design saves sample size, has better power, and efficiently assigns more patients to doses with higher efficacy levels...
- Breast cancer trends: a marriage between clinical trial evidence and epidemiologyDonald A Berry
J Natl Cancer Inst 99:1139-41. 2007
- Biomarker studies and other difficult inferential problems: statistical caveatsDonald A Berry
The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 34:S17-22. 2007..A related concern is subset analysis. I give a statistical argument that estrogen-receptor status is predictive of the benefits of chemotherapy in node-positive breast cancer...
- Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemiaFrancis J Giles
Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 21:1722-7. 2003..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
- Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patientsLynn G Dressler
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
J Clin Oncol 23:4287-97. 2005....
- Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methodsSwati Biswas
Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Genet Epidemiol 29:141-54. 2005..Such an approach will be even more important as additional information about the genetics of various cancers becomes available...
- Effect of screening and adjuvant therapy on mortality from breast cancerDonald A Berry
Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 353:1784-92. 2005..We used modeling techniques to assess the relative and absolute contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer mortality in the United States from 1975 to 2000...
- Characterization of BRCA1 and BRCA2 mutations in a large United States sampleSining Chen
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Clin Oncol 24:863-71. 2006..Existing studies have focused on Ashkenazi Jews (AJ) or on families from outside the United States. In this article, we consider the US population using the largest US-based cohort to date of both AJ and non-AJ families...
- Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869Anthony J Guidi
North Shore Medical Center, Salem, MA, USA
J Clin Oncol 20:732-42. 2002....
- The decrease in breast-cancer incidence in 2003 in the United StatesPeter M Ravdin
Department of Biostatistics, M D Anderson Cancer Center, Houston, USA
N Engl J Med 356:1670-4. 2007..The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded...
- Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysisJean Louis Pujol
Institut Universitaire de Recherche Clinique, Montpellier, Cedex, France
J Thorac Oncol 2:397-401. 2007....
- MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradationJer Yen Yang
Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Unit 108, Houston, TX 77030, USA
Mol Cell Biol 26:7269-82. 2006..This novel MDM2-regulated pathway is likely to play a biologically relevant role in cancer metastasis...
- CANCER INTERVENTION AND SURVEILLANCE MODELING NETWORKDonald Berry; Fiscal Year: 2004..Methods to be used include statistical modeling and simulation. A variety of sources of information will be used in model development. ..